The median overall survival was 18 4 months in the sunitinib alone group and 13 9 months in the nephrectomy sunitinib group.
Renal cell carcinoma survival after nephrectomy.
Renal cell carcinoma is the sixth most common cancer in the usa 1 where incidence rates have continued to rise in recent years 2 the prognosis of patients after a rcc diagnosis may follow an heterogeneous course on which the 5 year cancer specific survival rates may be as low as 38 in those patients with locally advanced or node positive disease 3 4.
Changes in future survival probability over time.
Organ confined disease pathologic stage pt1 2 confers the best prognosis with 5 year cancer specific survival rates after nephrectomy ranging from 71 to 97.
Survival rates for renal cell carcinoma are sometimes based on the percentage.
Abstract background cytoreductive nephrectomy has been the standard of care in metastatic renal cell carcinoma for 20 years supported by randomized trials and large retrospective studies.
No significant differences in response rate or progression free survival were observed.
1 for patients with locally advanced tumors 5 year cancer specific survival rates after nephrectomy decrease to 20 to 53 1 and once rcc has metastasized the 5 year survival rate is less than 10.
Conditional survival after nephrectomy for renal cell carcinoma rcc.